Indications
RITUXAN^® (Rituximab) is indicated for the treatment of patients with:

• Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
       • Weekly ×4 • Weekly ×8 • Bulky disease • Retreatment
• Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
• Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent,
  after first-line CVP chemotherapy
• Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other
  anthracycline-based chemotherapy regimens

BOXED WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of RITUXAN are fatal infusion reactions, tumor lysis
syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy
(PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events,
renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of RITUXAN
(incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia,
and lymphopenia.

For additional safety information, please see the full prescribing information, including BOXED
WARNINGS and Medication Guide at www.rituxan.com/lymphoma.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

This event, in partnership with ONSEdge, Inc., a subsidiary of the Oncology Nursing Society (ONS), is
ancillary to the ONS 34th Annual Congress.

Learning Objectives
At the end of this presentation, the participant will be able to

• Summarize past, current, and emerging trends in lymphoma diagnosis and staging
• Discuss the use of RITUXAN treatment after first-line CVP therapy in low-grade NHL
• Discuss the use of RITUXAN in combination with CVP as a first-line treatment for
  follicular NHL
• Identify successful patient management strategies through a team-care approach
• List nursing strategies for effective patient communication

Target Audience
This program is intended for oncology nurses interested in learning about an overview of the NHL disease
state, emerging trends in diagnosis and staging, and first-line management strategies with RITUXAN for
low-grade or follicular NHL.

Faculty
Wendy H. Vogel, MSN, FNP, AOCNP
Oncology Nurse Practitioner
Kingsport Hematology/Oncology Associates
Kingsport, TN

Program Outline

ONSEdge, Inc., has been assigned meeting space to provide an ancillary event during the ONS 34th Annual Congress, April 30–May 3, 2009, in San Antonio, TX. The ONS assignment of meeting space does not imply product endorsement, nor does the ONS assume any responsibility for the content.

RSVP deadline: 4/24/09—5 PM EST
RSVP NOW

The Lymphoma Education Series
In 2008, NHL was ranked the fifth most commonly diagnosed cancer in men and women in the United
States, with an estimated 66,120 new cases. As a response to this growing challenge, Genentech and
Biogen Idec, in partnership with ONSEdge, have designed an in-depth, 3-part educational series that will
present data on the delivery of care to patients with NHL.

Program 1: First-line management strategies with RITUXAN for certain types of CD20⁺ B-cell NHL
Program 2: RITUXAN as a single agent for the treatment of patients with relapsed or refractory, low-grade
or follicular NHL
Program 3: NHL patient education and caregiver burnout

Participants will receive a certificate upon completion of all 3 programs.
Note: NO continuing nursing education (CNE) contact hours will be awarded.

©2009 Genentech USA, Inc., and Biogen Idec Inc.  All rights reserved.  9649500  May 2009